How do cyclosporine and lifitegrast ophthalmic solutions alter T-cell mediated inflammation to provide long-term dry eye relief?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
How do cyclosporine and lifitegrast ophthalmic solutions alter T-cell mediated inflammation to provide long-term dry eye relief?
1 real search · 1 real-search pass
FDA prescribing information cyclosporine ophthalmic emulsion mechanism of action calcineurin NFAT dry eye lifitegrast LFA-1 ICAM-1 labelGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 1 queries…
Searches and sources
ChatGPT1 real searches · gpt-6
FDA prescribing information cyclosporine ophthalmic emulsion mechanism of action calcineurin NFAT dry eye lifitegrast LFA-1 ICAM-1 label Google ↗
- These highlights do not include all the information needed to use CEQUA safely and effectively. See full prescribing information for CEQUA. CEQUA® (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic useInitial U.S. Approval: 1983 · dailymed.nlm.nih.gov
- These highlights do not include all the information needed to use CYCLOSPORINE OPHTHALMIC EMULSION, 0.05% safely and effectively. See full prescribing information for CYCLOSPORINE OPHTHALMIC EMULSION, 0.05%. CYCLOSPORINE OPHTHALMIC EMULSION, 0.05% For topical ophthalmic use Initial U.S. Approval: 1983 · dailymed.nlm.nih.gov
- label · accessdata.fda.gov